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Abstract
Background: LIM kinase 1 (LIMK1), a LIM domain containing serine/threonine kinase, modulates
actin dynamics through inactivation of the actin depolymerizing protein cofilin. Recent studies have
indicated an important role of LIMK1 in growth and invasion of prostate and breast cancer cells;
however, the molecular mechanism whereby LIMK1 induces tumor progression is unknown. In this
study, we investigated the effects of ectopic expression of LIMK1 on cellular morphology, cell cycle
progression and expression profile of LIMK1 in prostate tumors.
Results: Ectopic expression of LIMK1 in benign prostatic hyperplasia cells (BPH), which naturally
express low levels of LIMK1, resulted in appearance of abnormal mitotic spindles, multiple
centrosomes and smaller chromosomal masses. Furthermore, a transient G1/S phase arrest and
delayed G2/M progression was observed in BPH cells expressing LIMK1. When treated with
chemotherapeutic agent Taxol, no metaphase arrest was noted in these cells. We have also noted
increased nuclear staining of LIMK1 in tumors with higher Gleason Scores and incidence of
metastasis.
Conclusion:  Our results show that increased expression of LIMK1 results in chromosomal
abnormalities, aberrant cell cycle progression and alteration of normal cellular response to
microtubule stabilizing agent Taxol; and that LIMK1 expression may be associated with cancerous
phenotype of the prostate.
Background
LIMK1 belongs to a family of unique LIM domain con-
taining serine/threonine kinases (LIMK1 and LIMK2). It
modulates actin dynamics by inactivating phosphoryla-
tion of cofilin, a member of the ADF (actin depolymeriz-
ing factor) family [1,2]. LIMK1 is expressed
predominantly in the brain but a modest expression of
LIMK1 has been noted in other organs. Recently, a novel
role for LIMK1 as an oncogene has been demonstrated in
prostate and breast cancer cells [3,4]. LIMK1 is upregu-
lated in malignant prostate tissues compared to histologi-
cally normal or benign prostates [3]. Biochemical and in
vivo studies have indicated that LIMK1 is involved in pro-
motion and maintenance of the invasive behavior in pro-
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static and breast cancer cells [3-5] and that when injected
in nude mice, breast cancer cells overexpressing LIMK1 are
capable of formation of osteolytic lesions in lower extrem-
ities and induction of tumor angiogenesis [4,5]. Indirect
evidence based on comparative genomic hybridization
analysis have indicated a significant correlation between
high-stage prostate cancers and chromosomal gains in the
short arm of chromosome 7 (7q11.2) [6], which includes
the region where LIMK1 is located (7q11.23).
The structural features of LIMK1 include two N-terminal
LIM domains in tandem, a single PDZ domain and a C-
terminal kinase domain [7,8]. LIMK1 also contains a sin-
gle nuclear localization signal and a single exit signal [9].
Functional activation of LIMK1 requires phosphorylation
at T508 mediated by p21-activated kinase PAK1 and ROCK
[10,11]. Activation of LIMK1 through ROCK promotes
accumulation of F actin through inactivation of cofilin, a
Rho phenotype, which results in formation of stress fibers
[11]. Importantly, LIMK1 is also activated by PAK1, which
is the effector molecule of the Rac-induced lamellipodia
formation or cell spreading [12].
LIMK1 undergoes a distinct pattern of activation during
mitosis, becoming hyperphosphorylated and activated at
the prometaphase and metaphase and gradually becom-
ing inactivated during telophase and cytokinesis [13,14].
Mitosis-specific activation and phosphorylation of LIMK1
is mediated by Cdk1 [14] but not through active PAK or
ROCK [14]. The activation pattern of LIMK1 corresponds
to the phosphorylation and dephosphorylation pattern of
cofilin during mitosis, which is essential for proper cyto-
kinesis [15]. Thus, maintenance of optimum concentra-
tions and activation of LIMK1 at specific mitotic phases
are critical for normal cell cycle progression. Cdk inhibitor
p57Kip  interacts with LIMK1 and sequesters it to the
nucleus [16] as a result of inhibition of Rho signaling by
Cip/Kip family members. LIMK1 exhibits contrasting
function of activation and inactivation of Cyclin D1
expression depending on the activation of Rac/Cdc42 or
Rho-Rho kinase pathways [17]. There also are conflicting
reports on expression of Cdk inhibitors (p21Cip1  or
p27Kip1) following inactivation of Rho-kinase or LIMK1
[18,19]. To date, it is uncertain whether an active LIMK1
is essential for progression of cells through the G1/S
phase. The other family member, LIMK2, also is activated
through ROCK at T505 [20]; and it is involved in meiosis
during maturation of Xenopus oocyte through phosphor-
ylation of cofilin [21]. Activation of ROCK also stimulates
cell cycle progression partly through increased cyclin A
levels via LIMK2 [22]. Nonetheless, LIMK1 and LIMK2
exhibit different cellular functions and subcellular locali-
zations [23,24].
We have noted that LIMK1 but not LIMK2 is overex-
pressed in highly aggressive and metastatic PC3 prostate
cancer cells and in prostate tumor tissues compared to
benign prostatic hyperplasia (BPH-1) cells and normal
prostatic epithelium. However, the precise role of LIMK1
in development of abnormal cellular processes, which
might facilitate prostate tumor growth and behavior, is
unclear. In this study, we demonstrate that increased
expression of LIMK1 is associated with accumulation of
chromosomal abnormalities, and development of cell
cycle defects in cells that naturally express lower concen-
trations of LIMK1. We also show that expression of LIMK1
is higher in prostate tumors with higher Gleason Scores
and incidence of metastasis.
Methods
Cell culture, antibodies and tumor samples
A benign prostatic hyperplasia cell line (BPH-1 cells)
(generated by Hayward et al. [25] and initially obtained as
a gift from P. Narayan, University of Florida) are routinely
maintained in our laboratory in DMEM containing 10%
FBS and antibiotic/antimycotic. BPH-1 cells were co-
transfected with the ORFs of human LIMK1 or LacZ
cloned in pIND vector and PVRxR plasmid (Invitrogen) to
establish stable cell lines (BPHL and BPHLacZ) as
described earlier [3]. Stable cells resistant to G418 (Invit-
rogen) (500 mg/ml) and Zeocin (Invitrogen) (50 ng/ml),
and expressing LIMK1 or LacZ upon induction with pon-
asterone A (ecdysone analog) were selected and main-
tained in DMEM/10%FBS/antibiotic/antimycotic. In
some cases, cells were induced with ponasterone A (Invit-
rogen) (5 μM) for 24 h prior to harvest. Anti-LIMK1
(Transduction Laboratories), anti-α-tubulin (Sigma) and
anti-glyceraldehyde-3-phosphate dehydrogenase (Bio-
genesis) monoclonal antibodies, and anti-γ-tubulin
(Sigma) polyclonal antibodies were used for immunob-
lotting, immunofluorescence and flow cytometry. Anti-
GAPDH antibodies were used in immunoblots to moni-
tor GAPDH expression as an internal control. A low-den-
sity tissue microarray (TMA) of prostate tumors
containing 50 prostate tumors and 3 uninvolved prostate
tissues was obtained from IMGENEX (Histo-Array,
IMGENEX 2.0 mm core diameter) [26]. The array pro-
vided by the manufacturer includes pathological reports
and histories of metastasis for individual tumor tissues.
The array was stained with anti-LIMK1 antibodies using
immunohistochemistry. The anti-LIMK1 antibody is
highly specific, does not cross react with LIMK2, and
yields a 72 kD polypeptide band in western blots.
Immunoblot, immunofluorescence and 
immunohistochemistry
Total cell lysates were resolved in SDS-PAGE and sub-
jected to immunoblotting using anti-LIMK1 and anti-
GAPDH antibodies. For indirect immunofluorescence,Molecular Cancer 2007, 6:40 http://www.molecular-cancer.com/content/6/1/40
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BPHLacZ and BPHL cells were plated on poly-L-lysine
coated glass coverslips and induced with ponasterone A
for 24 h prior to staining and in some cases treated with
Taxol (10 nM) for various time points. Cells were perme-
abilized and either singly or dually stained with combina-
tions of Alexa Fluor 488-conjugated phalloidin
(Molecular Probes), anti-α-tubulin and anti-γ-tubulin
antobodies. Alexa Fluor 488 or Cy3-conjugated anti-
mouse or anti-rabbit antibodies (Molecular Probes) were
used singly or in combination as the secondary antibody.
Nuclei were stained using 4–6-diamidino 2-phenylindole,
dilactic (DAPI, Molecular Probes). Fluorescent images
were visualized in an epifluorescent microscope (Nikon
TE300). The paraffin-embedded TMA was subjected to
immunohistochemistry (IHC) using a pepsin-based anti-
gen retrieval protocol (BioGenex, San Ramon, CA) and
anti-LIMK1 antibodies. A biotinylated multi-link goat
anti-immunoglobulin for mouse, rabbit, guinea pig and
rat was used as the secondary antibody. Nuclei were coun-
terstained with Hematoxylin QS (Vector Laboratories).
Positive signals were detected by HRP-conjugated strepta-
vidin and DAB as the chromagen (BioGenex Multi-Link
kit).
Immunostaining grade and statistical analysis
Immunostaining grades of the individual tumors in the
array were assessed on the basis of a scale of 0 (no stain-
ing) to +4 (intense staining) [27][28]. The percentage of
cells at each scale was estimated first and then the deci-
mal-equivalent of the percentage was multiplied by the
appropriate intensity score to obtain a weighted average
of the intensity score [29]. This average, which will vary
between 0 and 4, was referred to as the immunostaining
score. To determine the discriminative ability of the cyto-
plasmic staining and nuclear staining scores, an approach
based on receiver operating characteristic (ROC) curve
analysis was used. ROC curves for the two measurements
were calculated using the method of Pepe [30]. The cut
points were chosen based on the region where the slope
of the ROC curve was the greatest. Based on that cut point,
a chi-squared test was used to test for association between
clinical outcome and if the score exceeded the threshold.
The clinical outcome considered was the presence or
absence of metastases. This approach was taken relative to
a t-test because of the relatively limited sample size and
the fact that a difference in discriminative ability would
manifest in a way other as a difference in mean expres-
sion.
Cell synchronization and cell cycle analysis
BPHLacZ and BPHL cells were synchronized at the G1/S
boundary using double thymidine (2 mM) treatment.
Cells were treated with thymidine for 18 h, released from
thymidine block for 8 h in fresh culture medium and
blocked again with thymidine for 16 h. Cells were then
released from the block in fresh medium containing bro-
modeoxyuridine (BrDU) (10 μM). Ponasterone A was
added 24 h before the last release of the thymidine block
and cells were harvested at different times as specified.
Cells were treated with nocodazole (0.1 μg/ml) for 18 h
for synchronization at the G2/M boundary. Ponasterone
A was added also at the same time. Cells were released
from nocodazole block in fresh medium containing BrDU
and collected at different time points as specified. Cells
were reinduced every 24 h until they were harvested. Next,
cells were stained with FITC-conjugated anti-BrDU anti-
bodies and 7AAD using a BrDU labeling kit (Beckton
Dickinson) according to manufacturer's specification and
analyzed in a Flow cytometer (FACSCalibur, BD Bio-
sciences). Raw data were analyzed using CellQuest and
Modfit (BD Biosciences) software after elimination of
aggregates. Cells present inside the gated area were used
for calculation of percentage of cells in each phase.
Taxol treatment
Asynchronous BPHLacZ and BPHL cells were induced
with Ponasterone A and treated with Taxol (10 nM) for 24
h and 48 h. Cell cycle progression and DNA synthesis
were analyzed using BrDU incorporation and propidium
iodide staining. BrDU was added to monitor DNA synthe-
sis 16 h before harvesting. Cells were processed for flow
cytometry as described before. Growth of Taxol-treated
cells was monitored using MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide] assays which
produce formazan crystals upon cleavage of tetrazolium
rings by mitochondrial dehydrogenase from viable cells
using the protocol published elsewhere [31]. Values for
MTT assays are presented as mean +SD. The significance of
changes was determined by ANOVA (paired t-test) using
Statview software (Abacus Concepts, Calabasas, CA). Sta-
tistical significance was established at P < 0.05.
Results
Altered cell morphology and abnormal centrosome 
number were noted in cells overexpressing LIMK1
To understand the functional role of LIMK1 on cellular
morphology, we investigated the effects of ectopic expres-
sion of LIMK1 in benign prostatic hyperplasia (BPH-1)
cells. BPH-1 cells were chosen for these studies as these
cells express low levels of LIMK1. Two stable clones of
BPHL cells (BPHL1, BPHL2) showing significantly higher
levels of expression of LIMK1 compared to the parental
BPH-1 and BPHLacZ cells (Figure 1A) were selected and
used for subsequent studies. Analysis of morphology of
interphase cells following phalloidin staining for actin
indicated appearance of lamellipodia at the cell periphery
with accumulation of actin in BPHL cells (Figure 1B3 and
1B4), which was not seen in BPHLacZ cells (Figure 1B1
and 1B2). Immunofluorescence analysis also showed thatMolecular Cancer 2007, 6:40 http://www.molecular-cancer.com/content/6/1/40
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the expressed LIMK1 was predominantly cytoplasmic in
the interphase cells (data not shown).
To study the morphology of mitotic cells, we monitored
the distribution of α and γ tubulins in transfected cells as
components of microtubules and centrosomes respec-
tively, by immunofluorescence analysis. Our results
showed abnormal centrosome duplication and spindle
assembly, such as multipolar spindles and abnormal
chromosomal alignment at the equatorial plate in mitotic
BPHL cells. Appearance of abnormal/disorganized spin-
dles and multiple centrosomes were noted in 12% of the
cells undergoing mitosis (Figure 1C2 and 1C3). None of
these abnormalities was noted in mitotic BPHLacZ cells
(Figure 1C1). Furthermore, 9–10% of the BPHL cells
exhibited smaller DAPI stained chromosomal masses pre-
sumably micronuclei (Figure 1C4 and 1C5). Presence of
multinucleated cells (Figure 1C5) also was noted in BPHL
cells (5%), which express increased amounts of LIMK1
(Figure 1D).
LIMK1 expression transiently arrested cells at G1/S phase
The effect of increased expression of LIMK1 on cell cycle
progression specifically, progression of cells through the
G1/S phase were evaluated next. We used induced BPHL
and BPHLacZ cells synchronized at the G1/S boundary
using a double thymidine block. Replication patterns and
DNA contents of the cells released from the thymidine
block were monitored by continuous incorporation of
BrDU and staining with 7AAD at different time points
after release (Figure 2). Analysis of DNA contents indi-
cated that the percentage of the cells synchronized at the
G1/S boundary (0 h) (Initial G1, IG1) was similar (81.3%
BPHLacZ, 72.7%BPHL) for both cell types but a substan-
tial number of BPHL cells (22.7%) were sluggish in pro-
gression and remained in the G2 phase of the previous
cycle (initial G2 or IG2) as determined by the higher DNA
content (Figure 2C and 2D). At 6 h after release, almost
70% of the BPHLacZ cells had duplicated their DNA as
detected by BrDU incorporation, and moved to G2 phase
(Final G2 or FG2) (Figure 2A and 2C), whereas only 17%
of the BPHL cells duplicated their DNA and progressed to
FG2 (Figure 2B and 2D). A gradual decrease in the per-
centage of BPHLacZ cells in IG1 during next 16 h and con-
current increase in the percentage of cells in FG2 reaching
a peak at 10 h demonstrates progression of G1/S cells to
the G2/M phase. After 10 h, the percentage of BPHLacZ
cells in FG2 began to decrease and the anti- BrDU-FITC
stained cluster of cells started to accumulate in G1 of the
next cycle (Final G1, FG1) (Figure 2A and 2C). The com-
plete transition of BPHLacZ cells with a maximum
number of cells from IG1 to FG2 and then to FG1 was
achieved at 16 h after release of the thymidine block (Fig-
ure 2A and 2C). Interestingly, no distinct FG2 peak for
BPHL cells could be noted at any time. Also, about 20%
of the BPHL cells remained stationary in IG1 as indicated
by the lack of anti-BrDU incorporation in these cells. As a
result, while 69% of the BPHLacZ cells progressed to FG1
only 40% of the BPHL cells entered G1 of the next cycle
(FG1) (Figure 2D). The overall sluggish progression of
BPHL cells indicated a transient arrest of cells at G1/S
phase following induction of expression of LIMK1; this
was not observed in BPHLacZ cells.
Expression of LIMK1 delayed progression of cells through 
G2/M phase
Cells synchronized at the G2/M boundary were used next
to determine the effect of LIMK1 on progression of cells
through the G2/M phase. We monitored progression of
Ponasterone A induced cells for 24 h after release from 18
h nocodazole block. Two hrs after release from the noco-
dazole treatment, 40% of the total BPHLacZ cells
remained in IG1, 40% of the cells were synchronized and
arrested in IG2 and 20% of the cells started progressing
through the S phase and accumulated in FG1 as evident
from the BrDU incorporation (Figure 3A and 3C).
Between 6 h to 18 h after release, IG1 cells progressed
through the S and then G2/M phases, whereas cells
arrested at G2/M phase cycled to the G1 phase of the next
cycle (FG1). Almost all G2/M arrested BPHLacZ cells
(IG2) entered the next cycle after release and 80% of the
total cells were distributed in FG1, S and FG2 phases at 24
h (Figure 3A and 3C). At 2 h after release, 60% of the total
BPHL cells remained in IG1 and 40% of the cells were in
IG2 phases. No distinct BrDU incorporated cell popula-
tion could be detected as FG1 cells, which started pro-
gressing through the S phase (Figure 3B and 3D). At 12 h,
43% of the cells were in IG1 and did not incorporate
BrDU, 21% of the cells were in IG2, whereas 14% cells
were in each of the FG1 and FG2 phases. Cells designated
as FG2 cells incorporated BrDU and progressed through
the S phase. At 24 h, approximately, 30% of the BPHL
cells were in the IG1 phase, and had not incorporated
BrDU and 10% of the cells were in the IG2 phase (Figure
3B and 3D). About 30% of the cycling cells were in FG1
and 25% cells were in FG2 at 24 h.
LIMK1 prevented paclitaxel-mediated G2/M arrest and 
multinuclearity
Because our previous experiment indicated delayed tran-
sition of BPHL cells from G2/M to G1, we intended to
study the involvement of LIMK1 in mitotic process fol-
lowing paclitaxel (Taxol) treatment. Ponasterone A
induced transfected cells were treated with Taxol for 24 h,
and mitotic arrests were assessed by monitoring 7AAD
staining of the DNA contents. We have labeled cells con-
tinuously with BrDU (16 h) in order to examine progres-
sion of cells beyond G1. While asynchronous BPHLacZ
and BPHL cells showed similar profiles of G1, S and G2/
M cells and BrDU incorporation (Figure 4A and 4C histo-Molecular Cancer 2007, 6:40 http://www.molecular-cancer.com/content/6/1/40
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grams and dot plots) Taxol treatment induced a G2/M
arrest in BPHLacZ cells as evident by a larger peak of 4N
cells (Figure 4B histogram and dot plot, lower right quad-
rant) and low incorporation of BrDU (Figure 4B dot plot
upper left quadrant). A much smaller peak of 4N cells
were noted in Taxol treated BPHL cells indicating a lesser
number of cells in G2/M phase (Figure 4D histogram and
dot plot lower right quadrant). Taxol treated BPHL cells
were accumulated in G1 phase as indicated by a larger
peak of 2N cells ((Figure 4D, histogram and dot plot,
lower left quadrant). Quantitative analysis of distribution
of cells showed that a much higher percentage of
BPHLacZ cells (70%) were in G2/M phase compared to
BPHL cells (26%) following Taxol treatment (Figure 4E).
Immunofluorescence analysis of α tubulin and DAPI
staining showed that a significant number of Taxol-
treated BPHLacZ cells were with multiple nuclei (40%)
(Figure 4F and 4G) and about 25% of the cells were
arrested in metaphase (Figure 4F). No multinucleated
BPHL cell was detected following Taxol treatment. Only a
small percentage of these cells were in metaphase and
anaphase (2% and 6%, respectively) (Figure 4F and 4G).
MTT-based growth analysis indicated that Taxol treatment
Expression of LIMK1 in BPH-1 cells and analysis of cell morphology Figure 1
Expression of LIMK1 in BPH-1 cells and analysis of cell morphology. A: Western blot analysis of LIMK1 expression in BPH-1 
parental cells, BPHLacZ and clones of BPHL cells showing increased expression of LIMK1 in BPHL cells. Expression of GAPDH 
was used as the loading control. B. Phalloidin staining of F actin showing appearance of lamellipodia and ruffling membranes 
with accumulation of actin in BPHL cells (arrows) (3, 4). BPHLacZ cells showed more microspikes but no lamelipodia with 
actin accunulation (arrowheads) (1, 2) (scale bar: 5 μM). C. Panel 1 demonstrates normal mitotic spindle and centrosome 
number with proper chromosomal alignment at the metaphase plate in BPHLacZ cells (scale bar: 5 μM). Because of the vertical 
position of the cell only one centrosome is visible. Panels 2 and 3 show abnormal spindle architecture with multiple centro-
somes and altered chromosomal alignment in BPHL cells. Panel 4 demonstrates appearance of DAPI stained micronuclei in 
BPHL cells suggesting the presence of chromosomal instability (arrows). Panel 5 demonstrates the presence of multiple nuclei 
and micronuclei (arrows) in a cell. D: Western blot analysis of expression of LIMK1 in BPHL and BPHLacZ cells used for 
immunofluorescence analysis. Expression of LIMK1 in BPH-1 parental cells was used for comparison.Molecular Cancer 2007, 6:40 http://www.molecular-cancer.com/content/6/1/40
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induced growth retardation in BPHLacZ cells within 24 h
compared to untreated (vehicle) cells. No inhibition of
growth of Taxol treated BPHL cells was observed at 24 h
compared to DMSO treated cells. Growth patterns of
untreated BPHLacZ and BPHL cells showed an overall
slower proliferation rate of BPHL cells compared to
BPHLacZ cells (Figure 4H).
Expression of LIMK1 was associated with prostate cancer
To assess whether there is any correlations between
expression of LIMK1 and prostate cancer we have evalu-
ated the staining profile of LIMK1 in a number of prostate
tumors from patients with history of metastasis using
immunohistochemistry. The median age of patients at the
time of diagnosis was 68 years (range 44–88 years).
According to the TNM classification of tumors, 62% of the
patients showed history of either lymph node or distant
metastasis at the time of surgery or biopsy. Also, 88% of
the tumors exhibited Gleason Scores of 7 or above. Tumor
samples without any clinical history of distant or lymph
node metastasis had Gleason Scores between 6 to 10
(Table 1). A blinded immunohistochemical analysis indi-
cated a differential pattern of LIMK1 staining in tumors
and surrounding stromal areas. A variable cytoplasmic
staining of LIMK1 from very weak (Figure 5B1) to strong
(Figure 5B4) was noted in poorly differentiated prostate
adenocarcinomas. Nuclear staining for LIMK1 also varied
from no staining to strong staining in these samples. The
pattern of staining of the stroma was quite variable. In
general, there was no staining of the inflammatory cells.
The staining of smooth muscle cells was both cytoplasmic
and nuclear with usually one staining pattern clearly pre-
dominating. Expression of LIMK1 was higher in the stro-
mal cells in close proximity of the tumors in majority of
the cases compared to the stroma surrounding BPH. In
uninvolved normal glands of the prostate, the nuclei and
cytoplasm of basal cells stained moderately to strongly for
LIMK1 while there is weak staining for LIMK1 of the cyto-
plasm of the luminal cells. The strength and pattern of
staining of basal cells is similar to or stronger than stain-
ing of some of the smooth muscle cells of the stroma,
which stain with LIMK1 (Figure 5A1 and 5A2). Evaluation
of immunostaining grades in tumor areas indicates a rela-
tively broader range of cytoplasmic staining compared to
Flow cytometric analysis of progression of cells synchronized at the G1/S boundary Figure 2
Flow cytometric analysis of progression of cells synchronized at the G1/S boundary. A, B: Upper panel demonstrates two-
parameter histogram of distribution of BPHLacZ cells (A) and BPHL cells (B) in G1 (2N) and G2 (4N) phases at different times 
after release from thymidine block. Lower panel shows dot plots of BrDU incorporation in these cells as they progress 
through the S phase. Appearance of BrDU stained cluster of cells in G1 (upper left quadrant) at 12 h indicates entry of cells to 
the next cycle. C, D: Graphical representation of the percentage distribution of BPHLacZ cells (C) and BPHL cells (D) in initial 
G1 (IG1) (lower left quadrant), initial G2 (IG2) (lower right quadrant), final G1 (FG1) (upper left quadrant) and final G2 (FG2) 
(upper right quadrant) at different time points after release. Data shows temporary arrests of BPHL cells in G1/S phase. Similar 
profile was obtained in two separate experiments.
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nuclear staining (Figure 5C). Statistical analysis of the
immunostaining grades indicated that cytoplasmic stain-
ing has no association with incidence of metastasis (Chi-
squared p-value = 0.4), although the nuclear staining has
almost significant association (Chi-squared p-value =
0.07) (Figure 5D).
Analysis of relative intensity of nuclear stain between
groups of metastatic (57% positive) and nonmetastatic
(27% positive) tumors indicated higher immunostaining
scores in a larger percentage of metastatic tumors com-
pared to nonmetastatic ones (Figure 6A). When immu-
nostaining grades were correlated with Gleason Scores,
positive nuclear staining was observed in 17% of the
tumors with Gleason Scores of 6 whereas, 45% to 78% of
the tumors with 7 or higher Gleason Scores exhibited pos-
itive nuclear staining (Figure 6B, Table 1). Increased
nuclear staining intensity was also noted in tumors with
higher Gleason Scores (Figure 6B). Although all tumor
samples exhibited positive cytoplasmic staining for
LIMK1 in the luminal cells a propensity of increased
intensity of LIMK1 staining and higher Gleason Scores
could be noted (Figure 6C).
Discussion
In this study, the consequence of overexpression of LIMK1
in prostate epithelial cells, and any association of LIMK1
with prostate cancer have been assessed. Here we provide
evidence that an elevated expression of LIMK1 induces
abnormal centrosomal multiplication and generation of
multipolar spindles in BPH-1 cells. Disorganization of
spindles in BPHL cells may occur as a result of altered sta-
bility of microtubules. In a recent study, LIMK1 has been
shown to be involved in microtubule destabilization [32].
Appearance of multinucleated cells and micronuclei,
markers for genetic instability, also were evident in
response to increased expression of LIMK1. Although cen-
trosomal defects that often occur at the advanced stages of
cancer are believed to contribute to genetic instability by
altering fidelity of chromosomal segregation during mito-
sis, centrosomal defects also occur concurrently with chro-
mosomal abnormalities and cytological changes in early
Profile of cell cycle progression of G2/M synchronized cells Figure 3
Profile of cell cycle progression of G2/M synchronized cells. A: Upper panel: Two-parameter histogram of the distribution of 
BPHLacZ cells in G2/M (4N) and G1/S (2N) at different time points after release from nocodazole block. Lower panel: Dot 
plots of BrDU incorporation in these cells as they progressed through the S phase of the current cycle and the next cycle. B: 
Upper panel: Allocation of BPHL cells in G1 and G2 phases following release from G2/M block showing an overall sluggish tran-
sition of G2/M cells to G1. Lower panel: Incorporation of BrDU in G2/M synchronized BPHL cells shows transition of cells 
through the S phase. Note low uptake of BrDU by cells with 2N DNA content. C, D: Percentage distribution of BPHLacZ cells 
(C) and BPHL cells (D) in IG1, IG2, FG1 and FG2. Note slow progression of the subset of BPHL cells in G2/M (checkered bar). 
Data presented here is a representative of two separate experiments.
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stages of cancer [33-36]. Pihan et al demonstrated that
progressive dysfunction of centrosomes and misalloca-
tion of centrosomes occur during prostate cancer progres-
sion and such changes increase with increasing Gleason
Score in invasive cancer [37]. It is possible that the centro-
some and spindle defects induced by increased expression
of LIMK1 may play a role in phenotypic alterations in
BPHL cells. Such changes may also cause BPHL cells to
Effect of LIMK1 expression on Taxol treatment Figure 4
Effect of LIMK1 expression on Taxol treatment. A, C: Upper panel: Two-parameter histogram of cell cycle profile of asynchro-
nous BPHLacZ (A) and BPHL (C) cells. Lower panel: BrDU incorporation by asynchronous BPHLacZ and BPHL cells. B, D. 
Upper panel: Distribution of BPHLacZ cells (B) and BPHL cells (D) in different phases of the cell cycle following Taxol-treat-
ment for 24 h showing accumulation of BPHLacZ cells but not BPHL cells in G2/M containing 4N DNA. Lower panels show 
limited incorporation of BrDU in both cell types. E. Percentage distribution of BPHLacZ and BPHL cells in G1/S and G2/M 
phases with or without treatment with Taxol. F. Microscopic analysis of morphology of BPHLacZ and BPHL cells following 
Taxol treatment (scale bar: 5 μM). Arrows indicate multinucleated giant BPHLacZ cells as noted by DAPI staining. G: quantita-
tive analysis of multinucleated cells, cells in metaphase and cells in anaphase/telophase following Taxol treatment of BPHLacZ 
and BPHL cells. Five hundred cells were counted for percentage analysis. Data represents the profile obtained from two sepa-
rate experiments. H. MTT assays of the metabolic activity of cells treated with Taxol or DMSO. Equal amounts of cells were 
seeded and harvested at 24 and 48 h. Data shows a significant reduction in metabolic activity representing inhibition of cell pro-
liferation in BPHLacZ cells following Taxol treatments. BPHL cells showed proportionately increased metabolic activity with or 
without Taxol treatment. Data represents Mean+ SD of three separate experiments (* P < 0.001 compared to BPHLacZ 
DMSO 24 h; **P < 0.02 compared to BPHLacZ DMSO 48 h; • p < 0.01 compared to BPHLacZ Taxol 24 h; •• P < 0.05 com-
pared to BPHLacZ Taxol 48 h). Untreated BPHL cells showed a slower rate of growth compared to BPHLacZ cells.
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Expression of LIMK1 in prostate tumors Figure 5
Expression of LIMK1 in prostate tumors. A: Panel 1 demonstrates the strong staining of basal cells of benign prostatic glands 
with LIMK1 (solid arrow) (X400). In panel 2, there is a very weak staining of a poorly differentiated prostatic adenocarcinoma 
(X400). Moderate staining of scattered apparent smooth muscle cells can be identified in the stroma immediately adjacent to 
malignant cells (solid arrow). B: Panel 1 shows very weak staining of the cytoplasm of prostate cancer with no nuclear staining 
(X400). Panel 2 demonstrates no staining to strong nuclear staining of prostatic adenocarcinoma. The cytoplasmic staining var-
ies from weak to strong (X400). Panel 3 demonstrates very strong nuclear staining for LIMK1 for prostatic adnocarcinoma and 
moderate to strong cytoplasmic staining (X400). Panel 4 demonstrates very strong cytoplasmic staining for LIMK1 for prostatic 
adenocarcinoma. There is also variable nuclear staining of prostatic adenocarcinoma for LIMK1, which varies from no staining 
to moderate staining. C. Comparison of immunostaining scores between cytoplasmic and nuclear staining. D. Receiver operat-
ing characteristic (ROC) analysis of cyoplasmic (solid line) and nuclear staining (dotted line) in relation to incidence of metasta-
sis or no metastasis. ROC curve for nuclear staining showing a shift towards the y-axis indicates a better association of nuclear 
staining with the incidence of metastasis compared to cytoplasmic staining.
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Table 1: Distribution of tumors based on the Gleason Scores and history of metastasis with respect to nuclear and cytoplasmic staining 
of LIMK1
Gleason Scores # Samples Incidence of metastasis Cytoplasmic and 
Nuclear Staining
Cytoplasmic 
Staining Only
No Incidence of metastasis Cytoplasmic and 
Nuclear Staining
Cytoplasmic 
Staining Only
66 0 0 0 6 1 5
79 8 7 1 1 0 1
81 1 7 3 4 4 2 2
96 5 3 2 1 1 0
10 18 13 8 5 5 1 4Molecular Cancer 2007, 6:40 http://www.molecular-cancer.com/content/6/1/40
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become highly invasive compared to naturally noninva-
sive BPH-1 parental cells. Our earlier studies showed that
expression of LIMK1 made BPHL cells highly invasive
compared to BPHLacZ cells [3].
Our results on cell cycle analysis indicated an altered cell
cycle progression in BPHL cells, which showed a distinct
but transient arrest of cells at the G1/S phase and delayed
progression of cells through the G2/M phase. These find-
ings are in concurrence with the idea that chromosomal
abnormalities are intimately involved in generation of cell
cycle defects, which frequently become a phenotypic char-
acteristic of advanced cancers [38]. Although LIMK1
expression led to a transient arrest in G1/S phase it did not
inhibit cell proliferation as evident from BrDU incorpora-
tion, which is in contrast to the earlier reports on the
inhibitory effect of LIMK1 on NIH3T3 cell proliferation
[39]. The transient nature of G1 arrest implies a temporary
block that possibly depends on expression of one or more
key proteins. It is possible that the block is released when
concentrations of these proteins reach a threshold level.
Analysis of immunostaining intensity in tumor cells with respect to incidence of metastasis and Gleason Scores Figure 6
Analysis of immunostaining intensity in tumor cells with respect to incidence of metastasis and Gleason Scores. A: Relative 
intensity of the nuclear stain with respect to percentage of metastatic and nonmetastatic tumors. Only the cells showing posi-
tive nuclear staining of LIMK1 were used for the analysis. Distant Mets: Prostate tumors with history of distant metastasis; 
Lymph node Mets:Prostate tumors with history of lymph node metastasis. NonMets: Prostate tumors without any history of 
metastasis. % positive: Percentage of tumors showing nuclear stain. B: Relative immunostaining scores of nuclear stain in per-
centage of LIMK1 positive tumors with respect to Gleason Scores. C. Relative immunostaining scores of cytoplasmic stain in 
percentage of tumors with respect to Gleason Scores.
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Our experiments showing a delayed G2/M transition fol-
lowing increased expression of LIMK1 suggest the possi-
bility of cytokinesis defects rendered by increased
concentration of LIMK1. This observation supports the
earlier report showing that expression of LIMK1 in HeLa
cells induced cytokinesis defects [13,14]. Nonetheless,
this defect did not arrest cells permanently in the mitotic
phase. G2/M synchronized cells progressed to G1/S and
incorporated BrDU at a later time showing resumption of
the cell cycle progression. This observation suggests that
the concentration of LIMK1 needs to be tightly regulated
for proper progression of mitosis and cytokinesis. These
observations are supported by our MTT assay data, which
showed an overall slower growth rate of BPHL cells com-
pared to BPHLacZ cells. Expression of LIMK1 also pro-
moted resistance to Taxol induced metaphase arrest, cell
growth retardation and appearance of multinucleated
cells as a possible predisposition for apoptosis [40]. It is
speculated that the microtubule destabilizing effect of
LIMK1 interferes with the Taxol-induced microtubule sta-
bilization and inhibits normal cellular response to Taxol.
However, the exact mechanism whereby LIMK1 expres-
sion confers resistance to Taxol induced cellular responses
is not clear and is a subject for further study.
Our studies on expression of LIMK1 in prostate tumors
showed that all tumor samples were positive for weak to
strong cytoplasmic expression of LIMK1 compared to no
or very weak expression in the luminal cells of uninvolved
prostate glands. Expression of LIMK1 was noted in basal
cells of uninvolved tissues by IHC. Because basal cells are
highly proliferative in nature, they may require expression
LIMK1 for rapid cell growth. Furthermore, increased
expression of LIMK1 in stromal cells in close proximity to
the tumor areas in majority of the tumor samples may
have a functional significance in phenotypic changes asso-
ciated with advanced tumors. It has been documented
that reciprocal interactions between stroma and tumor
epithelium play important roles in acquisition of meta-
static phenotypes by the prostate tumors [41,42]. Our
studies also indicated a possible correlation between the
extent of nuclear or cytoplasmic expression of LIMK1 in
the luminal cells and Gleason Scores. Analysis of immu-
nostaining scores also showed an almost significant asso-
ciation between increased expression of nuclear LIMK1
and history of metastasis. Nonetheless, our study strongly
suggests an association between expression of LIMK1 and
prostate cancer.
To summarize, this study provides evidence that an ele-
vated expression of LIMK1 generates chromosomal insta-
bility and cell cycle defects. This report also shows that
overexpression of LIMK1 is associated with prostate can-
cer. The level of expression of LIMK1 achieved in our
experiment was either parallel to or less than that noted in
advanced prostate tumors and in PC3 prostate cancer
cells; this suggests that over expression of LIMK1 in pros-
tate tumors may suffice to elicit the biological effects
noted here. Furthermore, overexpression of LIMK1 con-
ferred resistance to Taxol-mediated mitotic arrest and
multinucleated giant cell formation. Taxol, an agent
widely used for treatment of cancer, works through the
inhibition of cell cycle by activation of mitotic check-
points. Expression of LIMK1 may deregulate mitotic
checkpoints in cancer cells whereby it can promote devel-
opment of resistance of advanced prostate cancer to
taxenes. Further studies are required to assess the rele-
vance of LIMK1- mediated deregulation of cell cycle in
progression of prostate cancer.
Conclusion
LIMK1 is involved in regulation of actin cytoskeleton and
microtubule dynamics and as a result, plays important
roles in cell division and cell behavior. Our studies imply
that the concentration of LIMK1 needs to be tightly regu-
lated for proper cell cycle progression and that up regula-
tion of LIMK1 may contribute to tumor progression
through altered cell cycle pattern and chromosomal
defects.
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